Colorectal cancer (CRC) is the third most common cancer and the second leading cause of
cancer-related death worldwide. Countless CRC patients undergo disease progression. As …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables
adaptability, limits therapeutic success, and remains incompletely understood. Single-cell …

Critical driver genomic events in colorectal cancer have been shown to affect the response
to targeted agents that were initially developed under the'one gene, one drug'paradigm of …

INTRODUCTION Cancer progression is fundamentally an evolutionary process, involving
multiple distinct steps from oncogenic transformation to metastatic dissemination to …

Colon cancer is the third most common cancer worldwide. Most colorectal cancer
occurrences are sporadic, not related to genetic predisposition or family history; however, 20 …

Both the timing and molecular determinants of metastasis are unknown, hindering treatment
and prevention efforts. Here we characterize the evolutionary dynamics of this lethal process …

Therapeutic advances in oncology have not fully translated to the treatment of metastatic
disease, which remains largely incurable. Metastatic subclones can emerge both early and …

Precision medicine requires an understanding of cancer genes and mutational processes,
as well as an appreciation of the extent to which these are found heterogeneously in cancer …

The accumulation of genetic alterations in driver genes is responsible for the development
and malignant progression of colorectal cancer. Comprehensive genome analyses have …